Tag: multiple myeloma

1. Approximately a quarter of multiple myeloma patients that had refractory disease despite treatment with a proteasome inhibitor, immunomodulatory agent, and daratumumab experienced treatment response with selinexor and dexamethasone. 2. Thrombocytopenia was a common adverse event in patients. Evidence Rating Level: 2 (Good)   Study Rundown: Relapse is common for multiple myeloma...
Multiple myeloma often develops from the precursor condition monoclonal gammopathy of undetermined significance (MGUS), which is detectable in peripheral blood. Similarly, the light-chain subtype of multiple myeloma is preceded by light-chain MGUS. Clinical guidelines recommend annual peripheral blood monitoring of serum immune markers for patients with intermediate-risk and high-risk...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve objective response rates amongst a majority of 33 patients with refractory or relapsed multiple myeloma participating in a phase 1 safety trial.  2. A majority of patients in this study...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve objective response rates amongst a majority of 33 patients with refractory or relapsed multiple myeloma participating in a phase 1 safety trial. 2. A majority of patients in this...
Autologous stem cell transplantation (ASCT) is commonly used in the treatment of multiple myeloma, though relapse is extremely common. Ixazomib is a proteasome inhibitor that has been suggested as a possible maintenance therapy for patients with multiple myeloma after they complete ASCT. In this multicenter, double-blind, randomized phase 3...
1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates compared to matched controls. 2. Risk of progression to multiple myeloma or another blood cell disorder was associated with identified adverse risk factors. Evidence Rating: 1 (Excellent) Study Rundown: MGUS is a...
1. The use of lenalidomide, bortezomib and dexamethasone (RVD) with transplantation was associated with a significantly longer progression-free survival compared to RVD therapy alone. 2. There was no difference in overall survival between the two therapeutic approaches. Evidence Rating Level: 1 (Excellent)  Study Rundown: The standard of therapy for newly diagnosed multiple...
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Daratumumab is a human monoclonal antibody that has shown efficacy and safety in phase 1 and 2 trials for patients with refractory or relapsed multiple myeloma. This phase 3 randomized trial investigated daratumumab as an adjunct to lenalidomide and dexamethasone in 569 patients...
1. The addition of daratumumab to standard therapy of lenalidomide and dexamethasone increased progression-free survival in relapsed or refractory multiple myeloma (MM). 2. Daratumumab was associated with a greater rate of infusion-related reactions and neutropenia compared to standard therapy alone. Evidence Rating Level: 1 (Excellent) Study Rundown: While the addition of proteasome...
1. Addition of daratumumab to bortezomib and dexamethasone increased the rate and length of progression-free survival. 2. The rates of thrombocytopenia and neutropenia had increased in the daratumumab group versus the control group. Evidence Rating Level: 1 (Excellent) Study Rundown: Major advances in the treatment of multiple myeloma (MM) have been made...